# Semaglutide vs Tirzepatide — Side-by-Side Comparison | ForYouPeptides

> Side-by-side comparison of semaglutide and tirzepatide: receptor class, clinical-trial efficacy, regulatory status, safety profile, and WADA status. A literature digest, not medical advice.

One receptor or two? A structured comparison of the GLP-1-only and dual GIP/GLP-1 approaches, drawn directly from head-to-head trial data.

## The short version

Both compounds on this desk work through the incretin axis — the gut-to-pancreas-to-brain hormone pathway that governs insulin secretion and hunger. Semaglutide activates one receptor in that pathway (GLP-1R); tirzepatide activates two (GIP-R and GLP-1R). In the head-to-head SURMOUNT-5 trial — the first randomised comparison between the two at maximum tolerated doses — tirzepatide produced -20.2% mean weight loss versus -13.7% for semaglutide over 72 weeks, a statistically significant difference (P<0.001) [1]. In glycaemic control, tirzepatide was likewise superior to semaglutide 1 mg across three doses in the SURPASS-2 trial [11].

Both share a similar GI side-effect profile, the same thyroid C-cell boxed warning, and a gallbladder signal tied to rapid weight loss. The main structural difference is one receptor versus two; the main practical difference, in trial data, is the magnitude of weight reduction achieved.

## Head-to-head comparison

| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| **Drug class** | GLP-1 receptor agonist (incretin mimetic) | Dual GIP + GLP-1 receptor agonist (dual incretin mimetic) |
| **Receptor targets** | GLP-1R | GIPR + GLP-1R |
| **Structure** | 31-amino-acid acylated GLP-1 analogue | 39-amino-acid GIP-based peptide with C20 fatty diacid arm |
| **Half-life** | ~7 days | ~5 days |
| **Dosing** | Once weekly (injection) or once daily (oral) | Once weekly (injection) |
| **Primary studied use** | T2D, obesity, cardiovascular risk reduction, CKD, MASH | T2D, obesity, sleep apnea |
| **FDA approval status** | FDA-approved (T2D, obesity, CV risk reduction, CKD [MASH 2025]) | FDA-approved (T2D 2022; obesity 2023; sleep apnea) |
| **WADA status** | Not specifically prohibited (verify current list) | Not specifically prohibited (verify current list) |
| **Head-to-head weight loss (SURMOUNT-5, 72 wk)** [1] | -13.7% | -20.2% (P<0.001 vs semaglutide) |
| **SURPASS-2 weight difference vs semaglutide 1 mg** [11] | Reference | -1.9 kg (5 mg), -3.6 kg (10 mg), -5.5 kg (15 mg) |
| **Gastrointestinal AEs** | Predominantly mild-moderate; nausea in ~1/3 of patients [5] | Predominantly mild-moderate; GI risk ~2.9x placebo in meta-analyses [9] |
| **Gallbladder / biliary disease** | Increased (cholelithiasis) [5] | Significantly increased composite RR 1.97 [9] |
| **Thyroid C-cell warning** | Yes — rodent-derived boxed warning [5] | Yes — rodent-derived boxed warning [8] |
| **Lean-mass concern** | Yes — meaningful lean-mass fraction in STEP body-composition substudies | Yes — ~25% lean mass in SURMOUNT-1 DXA substudy |
| **Weight regain on discontinuation** | Substantial (~11.6 pp mean regain in 1 year in STEP extension) | Substantial — SURMOUNT-4 shows regain after stopping |
| **Pregnancy** | Contraindicated (~5-week clearance after last dose) | Use under medical guidance; label advises caution |

**Citation key**: [1] SURMOUNT-5 (Aronne 2025); [5] Smits & Van Raalte safety review (2021); [8] Farzam & Patel StatPearls (2024); [9] Zeng et al. meta-analysis (2023); [11] Frias et al. SURPASS-2 (2021).

See the [references page](/references) for full citations.

## How to read this table

The comparison above draws directly from published randomised trials and peer-reviewed reviews — no manufacturer claims, no promotional framing. A few interpretive notes:

**On the head-to-head weight numbers**: SURMOUNT-5 was conducted at maximum *tolerated* dose for each participant, not a fixed dose; this design reflects clinical practice but means the weight-loss difference is somewhat dose-dependent. Semaglutide at a lower dose against tirzepatide at a higher dose is not an apples-to-apples potency comparison [1].

**On the GI profiles**: both drugs produce qualitatively similar GI side effects (nausea, constipation, diarrhea, slowed gastric emptying) for the same mechanistic reason — GLP-1R activation slows the gut. Tirzepatide's somewhat higher discontinuation rate in meta-analyses versus the comparator dulaglutide likely reflects its greater potency rather than a distinct toxicity.

**On the gallbladder signal**: both compounds show a biliary disease signal. The mechanism — rapid weight loss precipitating gallstones — is not specific to either drug and is a class-level finding for potent weight-loss agents.

**On approvals**: both are FDA-approved prescription medicines. This desk does not describe sources, costs, or access pathways; it reports what the clinical literature says about each compound's studied indications and safety profile.

---

A structured digest of peer-reviewed incretin research — organized like a briefing, not a prescription.